Onyx Pharmaceuticals, Inc. Message Board
-
lots of information, worth seeing!
-
Yes, it's still up over 30% from the Dec 31 close, which is sure beating the averages.
-
John, you have to stop paying such close attention to day to day price swings or caring about them.
-
need more info please
-
It is still very difficult to understand why this stock is susceptible to such wild price gyrations--in less than 10 minutes this morning it dropped more than $1. Is this due to lack of conviction on the part of buyers? Is it being manipulated by shorts? But then again the question is with such strong fundamentals why is it such an easy prey for the shorts?
- Reply to
Interesting article, uses a new sources of information, a new point of view for ONYX.
by tdavid21 •Apr 2, 2013 11:16 AMthanks just received the report
-
HUH..#$%$
- Reply to
Interesting article, uses a new sources of information, a new point of view for ONYX.
by tdavid21 •Apr 2, 2013 11:16 AMimportant information !
- Reply to
Interesting article, uses a new sources of information, a new point of view for ONYX.
by tdavid21 •Apr 2, 2013 11:16 AMI agree with this report
Sentiment: Buy
- Reply to
Proteasome Inhibitor Data Presentations at 14th International Myeloma Workshop
by johnpapas893 •Apr 2, 2013 11:28 AMThanks Bear. I look forward to reading about what you find out.
-
well prepared report!
- Reply to
Interesting article, uses a new sources of information, a new point of view for ONYX.
by tdavid21 •Apr 2, 2013 11:16 AMimportant report for ONXX!
Sentiment: Buy
-
thank you!
- Reply to
Proteasome Inhibitor Data Presentations at 14th International Myeloma Workshop
by johnpapas893 •Apr 2, 2013 11:28 AM"I am again impressed by how dramatically effective Kyprolis is for many MM patients. Some of the early participants in the trials have now been on the drug for almost 2 years and seem to be in effective remission"
Possible explanation/correlation for the action we see in SP? - Reply to
Proteasome Inhibitor Data Presentations at 14th International Myeloma Workshop
by johnpapas893 •Apr 2, 2013 11:28 AMHi, John, I have enrolled for the web broadcast on Friday (2pm PT), but I don't imagine I'll have enough patience to listen to it all. The website says that online enrollees should have received a password allowing them access to the abstracts, but I can't find any password in their e-mails. I don't expect anything earthshaking will be revealed here. A lot of the programs seem to be Big Picture discussions rather than reports of trials. If I learn anything new, I will post it here. On another note, perusing the posts on The Myeloma Beacon, I am again impressed by how dramatically effective Kyprolis is for many MM patients. Some of the early participants in the trials have now been on the drug for almost 2 years and seem to be in effective remission. It's becoming increasingly evident, I think, that Kyrpolis, rather than Velcade, should be the first line of treatment.
- Reply to
Interesting article, uses a new sources of information, a new point of view for ONYX.
by tdavid21 •Apr 2, 2013 11:16 AMContinue sharing this to us please. Thanks in advance.
-
This is a real once in a lifetime opportunity .Great Entry point before the Big FDA runup begins .GLTA
Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by in 2013 because of its very low burn-rate of just $1.2 Mil a year !
IGXT Submits next NDA to the FDA for an Anti-Migraine Versafilm last Week and another 3x More NDA/ANDA filings expected in 1H 2013 includes a potency drug which is better than Viagra . This Goldmine has 9x Drugs in their Mega Pipeline which will be all on the Market within next 2-3 years .
IGXT has NO DEBT and current Market cap of just $31 M is really a BIG BIG BARGAIN .
My Target is $8-12 within 2 Years .GLTA
Intelgenx (IGXT)
Market Cap : $31 M
Cash: $3.5 M
Burn-Rate : $1.2 M a year
Price : $0.63
Shares Out : 50 M ( 27 M shares are held by Insiders & Institutions)
"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.
March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.
----------------------- - Reply to
Interesting article, uses a new sources of information, a new point of view for ONYX.
by tdavid21 •Apr 2, 2013 11:16 AMfull detailed report. thanks
Sentiment: Buy
- Reply to
Interesting article, uses a new sources of information, a new point of view for ONYX.
by tdavid21 •Apr 2, 2013 11:16 AMvery helpful for investors!
Sentiment: Buy
-
Any views on how important these data presentations might be?
Google talks back in new voice search
CBSTV Videos - 9 hours agoMicrosoft News Byte: Xbox One Supports Ultra HD 4K Gaming
Wochit - 9 hours ago